Eli Lilly & Co (LLY)
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Ticker
- LLY
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $1.29T
- 52-week range
- $850.51 - $1475.25
Valuation
- Share price
- $1434.38 (close of Nov 16, 2026)
- P/E (TTM)
- 46.78x
- Price to book
- 31.97x
- Price to free cash flow
- 65.48x
- Enterprise value
- $1.33T
- Book value per share
- $45.15
Price performance
| Period | Change |
|---|---|
| 1 day | -0.63% |
| 5 days | +1.59% |
| 1 month | +14.11% |
| 3 months | +21.54% |
| 6 months | +42.74% |
| Year to date | +33.47% |
| 1 year | +39.90% |
| 3 years | +143.63% |
| 5 years | +456.56% |
| 10 years | +1,764.28% |
| All time | +35,344.14% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 0.81%
- Shares short
- 7.21M
- Days to cover
- 2.66
- Change since prior report
- +3.64%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed LLY trades
Josh Gottheimer · David Taylor · Gilbert Ray Cisneros · Jonathan Jackson · Julie Johnson · Lisa McClain · John Boozman · Marjorie Taylor Greene · Michael Rulli · Val Hoyle · Angus King · Bruce Westerman
Super investors holding LLY
Ken Griffin (Citadel) · Polen Capital Mgmt (Polen Capital Management LLC) · Mairs & Power (Mairs & Power Inc) · Ray Dalio (Bridgewater Associates) · Dodge & Cox (Dodge & Cox Funds) · George Soros (Soros Fund Mgmt) · Stanley Druckenmiller (Duquesne Family Office) · Bill Nygren (Harris Associates LP) · David Katz (Matrix Asset Advisors Inc)
Profitability and growth
- Return on equity
- 77.78%
- Return on invested capital
- 31.19%*
- Return on assets
- 18.35%
- Return on capital employed
- 34.47%*
- Gross margin
- 83.04%
- Net margin
- 31.67%
- EBITDA margin
- 43.91%
- Revenue growth
- 44.70%
- Net income growth
- 94.90%
- Free cash flow growth
- 138.62%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 1.53%
- Current ratio
- 1.39x
- Net debt to EBITDA
- 0.91x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $65.18B
- Cost of revenue
- $11.05B
- Gross profit
- $54.13B
- EBITDA
- $28.62B
- Net income
- $20.64B
- Earnings per share
- $23.00
- Research and development
- $13.34B
- Interest expense
- $895.00M
- Shares outstanding
- 897.30M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $65.18B | $54.13B | $20.64B | $23.00 |
| 2024-12-31 | $45.04B | $36.63B | $10.59B | $11.76 |
| 2023-12-31 | $34.12B | $27.04B | $5.24B | $5.82 |
| 2022-12-31 | $28.54B | $21.91B | $6.24B | $6.93 |
| 2021-12-31 | $28.32B | $21.01B | $5.58B | $6.15 |
| 2020-12-31 | $24.54B | $19.06B | $6.19B | $6.82 |
| 2019-12-31 | $22.32B | $17.60B | $8.32B | $8.93 |
| 2018-12-31 | $21.49B | $16.81B | $3.23B | $3.14 |
| 2017-12-31 | $19.97B | $15.53B | -$204.10M | -$0.19 |
| 2016-12-31 | $18.31B | $14.15B | $2.74B | $2.59 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 83.04% | 31.67% | 77.78% | 31.19%* |
| 2024-12-31 | 81.31% | 23.51% | 74.20% | 23.73%* |
| 2023-12-31 | 79.25% | 15.36% | 48.23% | 15.87%* |
| 2022-12-31 | 76.77% | 21.88% | 57.95% | 24.34%* |
| 2021-12-31 | 74.18% | 19.71% | 60.97% | 22.16%* |
| 2020-12-31 | 77.66% | 25.24% | 106.33% | 28.39%* |
| 2019-12-31 | 78.85% | 37.27% | - | 27.23%* |
| 2018-12-31 | 78.22% | 15.04% | 29.63% | 15.56%* |
| 2017-12-31 | 77.73% | -1.02% | -1.75% | 5.00%* |
| 2016-12-31 | 77.28% | 14.95% | 19.44% | 11.93%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $7.27B | $40.87B |
| 2024-12-31 | $3.42B | $28.53B |
| 2023-12-31 | $2.93B | $18.32B |
| 2022-12-31 | $2.21B | $14.74B |
| 2021-12-31 | $3.91B | $15.35B |
| 2020-12-31 | $3.68B | $16.59B |
| 2019-12-31 | $2.44B | $13.82B |
| 2018-12-31 | $7.41B | $9.20B |
| 2017-12-31 | $8.03B | $9.94B |
| 2016-12-31 | $6.04B | $8.37B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $8.97B | $626.00M |
| 2024-12-31 | $3.76B | $646.00M |
| 2023-12-31 | $792.00M | $629.00M |
| 2022-12-31 | $5.73B | $371.10M |
| 2021-12-31 | $6.06B | $342.80M |
| 2020-12-31 | $5.11B | $308.10M |
| 2019-12-31 | $3.80B | $312.40M |
| 2018-12-31 | $4.31B | $279.50M |
| 2017-12-31 | $4.54B | $281.30M |
| 2016-12-31 | $3.81B | $255.30M |
Dividend history
- Most recent payment
- Nov 13, 2026
- Paid in the last twelve months
- $6.92
| Payment date | Dividend per share |
|---|---|
| 2026-11-13 | $1.73 |
| 2026-08-14 | $1.73 |
| 2026-05-15 | $1.73 |
| 2026-02-13 | $1.73 |
| 2025-11-14 | $1.50 |
| 2025-08-15 | $1.50 |
| 2025-05-16 | $1.50 |
| 2025-02-14 | $1.50 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-29 | Sep 2026 | $5.38 |
| 2026-08-05 | Jun 2026 | $6.01 |
| 2026-04-30 | Mar 2026 | $7.06 |
| 2026-02-04 | Dec 2025 | $6.99 |
| 2025-10-30 | Sep 2025 | $6.02 |
| 2025-08-07 | Jun 2025 | $5.61 |
| 2025-05-01 | Mar 2025 | $3.52 |
| 2025-02-06 | Dec 2024 | $5.03 |
Filings and sources
- Company website
- lilly.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades